NEW YORK (GenomeWeb) – Investment bank Janney today downgraded Danaher's shares to a Neutral rating from a previous Buy rating, but kept its fair value estimate for the company at $95 per share.

In a research note, analyst Paul Knight said that Danaher "has more work to do on optimizing its portfolio, and we expect smaller organic growth surprises than other peers." In particular, he noted Danaher's 2.5 percent organic growth in the first quarter, which Knight said was the lowest among large cap science peers, such as Thermo Fisher Scientific, Waters, and Agilent Technologies.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.